REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Aug 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-20

Reporting Person: LAROSA JOSEPH J (EVP General Counsel and Secret)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-20	Common Stock	M	10000	$179.13	Acquired	23182	Direct
2021-08-20	Common Stock	F	6575	$664.85	Disposed	16607	Direct
2021-08-23	Common Stock	S	3383	$661.8	Disposed	13224	Direct
2021-08-23	Common Stock	S	41	$665.4	Disposed	13183	Direct
2021-08-23	Common Stock	S	1	$666.22	Disposed	13182	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-20	Non-Qualified Stock Option (right to buy)	$179.13	M	10000	Disposed	2022-12-14	Common Stock (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3186	Indirect
Common Stock	314	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 41 shares of Company stock on August 23, 2021 at prices ranging from $665.21 to $665.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

F3: The stock option award vests in four equal annual installments, commencing one year after the date of grant.